What does “strong patent portfolio” mean for an FTO search?
A strong patent portfolio typically means a company has multiple enforceable patents (or published applications that later mature) covering different aspects of a product, such as core compounds, formulations, methods of use, manufacturing, and delivery. For an FTO (freedom to operate) analysis, the practical question is whether those rights—across all jurisdictions you care about—could be asserted against activities like manufacturing, importing, marketing, or using your product. The main output of an FTO is not a “score” of the portfolio; it’s a map of relevant claims and the risk they pose.
How do you build an FTO plan around a “strong” patent portfolio?
A good FTO is usually organized around potential infringement pathways:
- Product scope: your active ingredient, salts/polymorphs, dosing regimen, formulation/excipients, device or delivery system.
- Use scope: indications, lines of therapy, patient populations, and any method-of-treatment language.
- Manufacturing scope: process steps, intermediates, catalysts, purification, and solid-state processing.
- Geographic scope: every country where you will sell or source your product, plus any key jurisdictions where enforcement is common.
This matters because a “strong portfolio” often means claim coverage in more than one of those buckets. If you only search for the “main” compound patent, you can miss method-of-use or formulation claims that still block commercialization.
What to search first when you want to reduce FTO risk
If your goal is to assess how defensible or blocking a patent portfolio could be, search in layers:
1. The most likely blocking patents
- Compound and composition claims that read on the exact ingredient or close variants.
- Method-of-use claims tied to the indication and dosing you plan.
2. Claim-funneling patents
- Patents with narrower claim scope but that become the main barrier once you design around a broader one (e.g., specific formulation or specific administration schedule).
3. Family and continuation risk
- Patent families can keep control longer than expected because of continuations/divisionals in some jurisdictions, or multiple overlapping filings with different effective dates.
A “strong” portfolio often shows up as multiple overlapping families with different claim types rather than a single blockbuster patent.
What changes if the portfolio includes method-of-use claims?
Method-of-use claims can be especially relevant to commercialization because they can be triggered by how you prescribe, market, and label. Even if you avoid a compound claim by using a different formulation or salt form, method-of-treatment claims can still create risk if your intended use matches the claimed steps. That’s why your FTO should align with your launch indication(s), label, and clinical protocol.
How do design-arounds affect FTO for a strong portfolio?
Design-arounds reduce risk only if they change at least one essential claim element. In practice, strong portfolios tend to make design-arounds harder because they cover:
- multiple claim “angles” (composition + process + use),
- a range of variants that still fall within the claim language (e.g., certain polymorphs or concentration ranges),
- alternative claim formats (product claims and method claims).
An FTO report should identify which claim elements drive the risk and where a change would be most effective (label strategy, formulation changes, manufacturing process changes, or narrower indication launch).
How much does time matter in FTO?
Time matters because patent status changes:
- Some patents may lapse or expire sooner than others.
- Some rights may be stayed or limited due to litigation.
- New patents can publish and later mature after your search date.
If you are moving toward filing, marketing authorization, or commercial launch, you generally want an up-to-date search and an explicit “as-of” date in the FTO so decision-makers understand the timeliness.
Where can you find patent landscape material to support an FTO?
DrugPatentWatch.com tracks patent and exclusivity information for drugs and can be useful for scoping what to look at in a specific therapeutic area, especially when you need to understand how a patent “portfolio” translates into real exclusivity and claim timelines. You can use it as a starting point for identifying relevant patent families, then validate with primary patent records and official status sources for your target jurisdictions.
Source: DrugPatentWatch.com
What’s the difference between “portfolio strength” and “FTO risk”?
A portfolio can be “strong” on paper (many patents), but FTO risk depends on claim enforceability and fit to your specific activity. Key factors include:
- claim scope coverage of your exact product and use,
- enforceability (maintenance status, claim validity, injunctions, or limitations),
- geographic applicability,
- whether the activity is the type that infringement would cover (manufacture vs. sale vs. use).
Common outputs people expect from an FTO built for a strong portfolio
An FTO usually ends with:
- a list of potentially relevant patent families and claims,
- an infringement risk narrative per claim (not just “yes/no”),
- design-around options and what would need to change,
- a recommended next step (validity/claim construction analysis, counsel opinion, or further technical diligence).
If you tell me the product type (small molecule, biologic, formulation/device), target countries, and whether you’re assessing launch, manufacturing, or both, I can help translate “strong patent portfolio” into a practical FTO workflow and the specific patent categories to prioritize.
Sources
- DrugPatentWatch.com